A Phase IV, Open-Label Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-alpha Therapy

Trial Profile

A Phase IV, Open-Label Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-alpha Therapy

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 27 Jun 2016

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Sponsors Elan Pharmaceuticals
  • Most Recent Events

    • 16 Oct 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top